Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030

The article identifies Vertex Pharmaceuticals, Iovance Therapeutics, and Summit Therapeutics as healthcare stocks poised for significant growth through 2030. Vertex, already successful with its cystic fibrosis franchise, anticipates further growth from Journavx for acute pain and potential approvals for IgA nephropathy and type 1 diabetes treatments. Iovance, with its FDA-approved T-cell therapy Amtagvi for melanoma, is exploring its application across various cancers. Summit Therapeutics, lacking current market products, anticipates success with ivonescimab, an immunotherapy licensed from Akeso, showing promise in treating non-small-cell lung cancer.

Analysis

The healthcare sector is presented as resilient and poised for growth, driven by consistent demand and aging demographics, offering opportunities in drugmaker stocks. Vertex Pharmaceuticals (VRTX), despite a Q1 earnings miss attributed to illegal drug sales in Russia and a temporary pause in its VX-522 study, is highlighted for its strong cystic fibrosis franchise and significant growth potential from new products. Notably, Journavx, a non-opioid treatment for acute pain, received FDA approval earlier this year and is anticipated to be a major revenue driver. Vertex also expects to file for accelerated approval of povetacicept for IgA nephropathy in H1 2026 and for zimislecel in severe type 1 diabetes next year. Iovance Therapeutics (IOVA) has Amtagvi, the first FDA-approved T-cell therapy for a solid tumor (advanced melanoma), on the market. While Q1 Amtagvi sales were below expectations due to facility maintenance, the company is actively pursuing label expansion for Amtagvi across multiple cancer types, including non-small-cell lung cancer (NSCLC), and in combination therapies. Summit Therapeutics (SMMT), currently without an approved product, holds promise with its licensed immunotherapy, ivonescimab, which has shown superior performance against Keytruda and Tevimbra in ex-U.S. NSCLC studies conducted by Akeso. Summit anticipates top-line results from its Harmoni study for ivonescimab in second-line NSCLC by mid-2025 and is exploring its use in other cancers, indicating a high-growth trajectory if clinical trials prove successful despite its current $17 billion market cap and lack of marketed products.

Key Decisions for Investors

• Investors should consider the long-term growth trajectory of the healthcare sector, focusing on drug developers with innovative pipelines addressing significant unmet medical needs.
• For Vertex Pharmaceuticals (VRTX), monitor the commercial uptake of Journavx and the progression of its late-stage pipeline candidates povetacicept and zimislecel, while being cognizant of recent Q1 challenges and the temporary pause on the VX-522 study.
• Evaluate Iovance Therapeutics (IOVA) based on its ability to navigate the complexities of launching Amtagvi, a novel T-cell therapy, and achieve successful label expansions into broader oncology indications.
• Summit Therapeutics (SMMT) presents a higher-risk, potentially high-reward investment, with the mid-2025 Harmoni study results for ivonescimab serving as a critical near-term catalyst; the lack of an approved product necessitates careful risk assessment.
• Consider potential headwinds such as clinical trial outcomes, regulatory approvals, and commercial execution challenges specific to each company when allocating capital within the biotech sub-sector.